In addition to potential prognostication value of the c-myc molecule, targeting c-myc is becoming up-to-date because c-myc is involved in several types of other human cancer [14] and it has been discovered that some drugs, such as BET bromodomains does inhibit c-myc dependent transcription and BET family inhibitors are investigated actually for the neoplastic treatment [15]. The gene discussed is DNER; the disease is cancer.